Corcept Therapeutics Inc (CORT)
43.93
+0.65
(+1.50%)
USD |
NASDAQ |
Sep 27, 16:00
43.98
+0.05
(+0.11%)
After-Hours: 20:00
Corcept Therapeutics SG&A Expense (Annual): 184.26M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 184.26M |
| December 31, 2022 | 152.85M |
| December 31, 2021 | 122.36M |
| December 31, 2020 | 105.33M |
| December 31, 2019 | 100.36M |
| December 31, 2018 | 81.29M |
| December 31, 2017 | 62.42M |
| December 31, 2016 | 45.24M |
| December 31, 2015 | 36.95M |
| December 31, 2014 | 34.92M |
| December 31, 2013 | 31.24M |
| December 31, 2012 | 25.41M |
| Date | Value |
|---|---|
| December 31, 2011 | 11.33M |
| December 31, 2010 | 8.488M |
| December 31, 2009 | 5.877M |
| December 31, 2008 | 5.746M |
| December 31, 2007 | 4.867M |
| December 31, 2006 | 5.042M |
| December 31, 2005 | 4.084M |
| December 31, 2004 | 4.494M |
| December 31, 2003 | |
| December 31, 2002 | 5.531M |
| December 31, 2001 | 2.616M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
100.36M
Minimum
2019
184.26M
Maximum
2023
133.03M
Average
122.36M
Median
2021
SG&A Expense (Annual) Benchmarks
| Akebia Therapeutics Inc | 100.23M |
| Bioventus Inc | 303.88M |
| Bruker Corp | 730.10M |
| Catalyst Pharmaceuticals Inc | 133.71M |
| ADMA Biologics Inc | 59.02M |